Direct thrombin inhibitor use during extracorporeal membrane oxygenation

Michael Colin Mowrer, Lakshmi Raman, Ali McMichael

Research output: Chapter in Book/Report/Conference proceedingChapter


Systemic anticoagulation is necessary during extracorporeal membrane oxygenation (ECMO) to prevent circuit clotting. Unfractionated heparin (UFH) is the most widely used anticoagulant for ECMO, but has several clinical disadvantages including risk of development of heparin-induced thrombocytopenia (HIT), need for antithrombin (AT) for maximum effect, and variable dosing in pediatric patients secondary to deficiencies in hemostasis proteins [1, 2]. Direct thrombin inhibitors (DTIs) are potential effective and safe alternatives for anticoagulation in patients undergoing ECMO [3, 4].

Original languageEnglish (US)
Title of host publicationExtracorporeal Membrane Oxygenation
Subtitle of host publicationTypes, Medical Uses and Complications
PublisherNova Science Publishers, Inc.
Number of pages9
ISBN (Electronic)9781536190649
StatePublished - Dec 21 2020


  • Anticoagulation
  • Direct thrombin inhibitors
  • ECMO

ASJC Scopus subject areas

  • Medicine(all)
  • Health Professions(all)


Dive into the research topics of 'Direct thrombin inhibitor use during extracorporeal membrane oxygenation'. Together they form a unique fingerprint.

Cite this